Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menveo Booster Study in Healthy Individuals
NCT02986854Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine in meningococcal infection (3 arms), sponsored by GSK. Primary endpoint: Percentages of Subjects With Human Serum Bactericidal Antibody (hSBA) Seroresponse Against Neisseria Meningitidis Serogroups A, C, W and Y at Day 29. Started Dec 2016; status: completed.
02
Drugs
Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT02986854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986854.